NEUROCRINE BIOSCIENCES, INC.
๐ธ๐ชSweden
- Country
- ๐ธ๐ชSweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 50
- Registration Number
- NCT03224325
- Locations
- ๐บ๐ธ
California Clinical Trials Medical Group/PAREXEL, Glendale, California, United States
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 67
- Registration Number
- NCT03214588
- Locations
- ๐บ๐ธ
UCLA Ataxia Center, Los Angeles, California, United States
๐บ๐ธOhio State University Wexner Medical Center, Columbus, Ohio, United States
๐บ๐ธUSF College of Medicine, Tampa, Florida, United States
A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT03101293
- Locations
- ๐บ๐ธ
PRA Health Sciences, Lenexa, Kansas, United States
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT03065192
- Locations
- ๐บ๐ธ
University of California, San Francisco (UCSF), San Francisco, California, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
๐บ๐ธUniversity of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
- Conditions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 70
- Registration Number
- NCT03062033
- Locations
- ๐บ๐ธ
Neurocrine Clinical Site, Bellevue, Washington, United States
A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 12
- Registration Number
- NCT02959892
- Locations
- ๐ฌ๐ง
Hammersmith Medicines Research, London, United Kingdom
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 155
- Registration Number
- NCT02879578
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 114
- Registration Number
- NCT02748694
- Locations
- ๐บ๐ธ
Parexel Early Phase Clinic Unit- Los Angeles, Glendale, California, United States
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 161
- Registration Number
- NCT02736955
Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 20
- Registration Number
- NCT02716987
ยฉ Copyright 2024. All Rights Reserved by MedPath